Interpretation of WHO global tuberculosis report 2024

doi:10.19983/j.issn.2096-8493.2024164

Abstract

Abstract:

In October 2024, the World Health Organization released the global tuberculosis report 2024. While emphasizing previous strategies, the report also introduces new strategic goals. The authors provide a key interpretation of the report, focusing on the global tuberculosis burden, case reporting, treatment outcomes, diagnostic and treatment innovations, and updates to guidelines. The aim is to offer a comprehensive understanding of global TB prevention and control strategies, actions, and progress, serving as a reference for colleagues in the field of tuberculosis.

Key words: Tuberculosis, Research, World Health Organization, Consensus development conference

CLC Number:

Hu Xinyang, Gao Jingtao. Interpretation of WHO global tuberculosis report 2024[J]. Journal of Tuberculosis and Lung Disease , 2024, 5(6): 500-504. doi: 10.19983/j.issn.2096-8493.2024164

Figures/Tables 2

时间	举措
2024年9月	建立结核病临床试验平台: WHO组织召开了旨在建立“临床试验平台”的沟通会,以便快速跟踪和评估有前景的抗结核治疗方案进展情况。该平台将会建立一个通用型方案以用于同时评估多个治疗方案,包括采用适应性平台设计。此举有望提高临床试验效率并推进不同国家、申办方、投资方及民间组织间的资源共享与合作
2024年5月	成立结核病疫苗加速理事会: WHO自2023年9月成立了结核病疫苗加速理事会以来召开了一系列会议,以收集有关理事会在加速将科学突破转化为有效和可及的结核病疫苗方面的工作建议。经过WHO和理事会代表的讨论,对2024—2025年理事会第一个任期的关键目标和重要里程碑达成共识
2024年3月	分享结核病筛查和预防性治疗的投资案例: WHO发布了结核病筛查和预防性治疗的投入产出实践案例,与2023年联合国大会结核病高级别会议确定的结核病预防性治疗覆盖率的全球目标一致。该项实践由巴西、格鲁吉亚、肯尼亚和南非四国合作开展,实践指出通过相对适度的投资可获得显著的健康和经济获益:每投入1美元可带来高达39美元的社会回报
2024年3月	建立结核病测序门户网站: WHO启动了结核病测序门户网站建立,以分享最新的结核分枝杆菌测序和表型知识库。该网站是由FIND和UNITAID共同开发,可提供了超过56000个序列并实现WHO突变目录中数据的可视化
2024年2月	建立结核病研究转化为全球政策指南定期沟通机制: WHO每年举行结核病研究转化沟通会,旨在评估和讨论不断迭代的循证依据如何转化为全球结核病政策指南
2023—2024年	推动金砖国家结核病研究网络工作: WHO持续参与和支持多个研究平台和网络,包括承担金砖国家结核病研究网络秘书处工作,以深化金砖国家合作,加速终止结核病的步伐

References 8

[1]	World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
[2]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis-rapid diagnostics for tuberculosis detection, third edition. Geneva: World Health Organi-zation, 2024.
[3]	World Health Organization. Co-administration of treatment for drug-resistant tuberculosis and hepatitis C: rapid communication. Geneva: World Health Organization, 2024.
[4]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 6: tuberculosis and comorbidities. Geneva: World Health Organization, 2024.
[5]	World Health Organization. WHO operational handbook on tuberculosis:Module 6: tuberculosis and comorbidities, second edition. Geneva: World Health Organization, 2024.
[6]	World Health Organization. Key updates to the treatment of drug-resistant tuberculosis:rapid communication,August 2024. Geneva: World Health Organization, 2024.
[7]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: Prevention-tuberculosis preventive treatment, second edition. Geneva: World Health Organization, 2024.
[8]	World Health Organization. Diagnosis of tuberculosis and detection of drug-resistance:rapid communication. Geneva: World Health Organization, 2024.

指标	全球目标	当前进展
结核病治疗覆盖率 (每年估算的新发患者中给予有质量保证的诊断和治疗的结核病患者所占比例)	到2027年达到90% (即2023—2027年5年期间全球将为4500万例患者提供治疗,包括450万例儿童和150万耐药结核病患者)	2023年为75%
结核病预防性治疗覆盖率 (对结核病高危人群开展结核病预防性治疗的人群所占比例)	到2027年达到90% (即2023—2027年5年期间全球为4500万例结核病高危人群提供预防性治疗,包括3000万例结核病患者家庭密切接触者和1500万例人类免疫缺陷病毒感染者	2023年结核病家庭密切接触者为21%,人类免疫缺陷病毒感染者为56%
结核病快速诊断技术覆盖率 (结核病患者中首选WHO推荐的快速分子生物学检测技术确诊的患者所占比例)	到2027年达到100%	2023年为48%
为结核病患者提供健康及相关照护服务的覆盖率	到2027年达到100%
安全有效的新型结核病疫苗的可及性	最好在5年内开始推广应用	至2024年8月已有6种疫苗处于Ⅲ期临床试验阶段
每年为均质化获得高质量结核病预防、诊断、治疗和关怀所投入的经费	到2027年达到220亿美元,到2030年达到350亿美元	2023年是57亿美元
每年为结核病相关研究投入的经费	到2027年达到50亿美元	2022年是10亿美元

[1]	Chen Yu, Li Xiaorui, Wang Miaoran, Zhang Yuqi, Liu Chang, Wang Zhaohua, Shi Jie, Fan Lichao, Yin Zhihua, Xie Jianping. The research progress on the role of metal ions in tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 102-112.
[2]	Xu Yannan, Fang Zihao, Zhao Wenli, Zheng Jiaxiong, Liu Suyang, Lin Jianxiong, Ji Liwei, Chang Qiaocheng. Characterisation of isoniazid-resistant Mycobacterium tuberculosis mutations in China [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 14-21.
[3]	Wan Ying, Pang Xuewen, Zhang Fan. Evaluation on effect of health promotion for tuberculosis prevention and control in Tianjin City from 2010 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 22-29.
[4]	Zhao Yongnian, Zhang Lijie, Wang Tongmin. Analysis of the epidemiological characteristics of reported pulmonary tuberculosis in Xinjiang Production and Construction Corps, 2014—2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 30-34.
[5]	Zheng Jianli, Wu Yumei, Zhang Shili, Du Zixian, Li Turong, Chen Shisheng, Lin Wenge. Cost-effectiveness analysis of active tuberculosis screening among high-risk populations in Longyan City, Fujian Province [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 35-39.
[6]	Yang Yan, Dong Wen, Chen Jianjun, Zhang Yu. Epidemiologic characteristics of pulmonary tuberculosis in Zhuxi County, Shiyan City (2014-2023) [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 40-45.
[7]	Qi Wei, Zhao Enyi. The epidemic characteristics and the trends of pulmonary tuberculosis in elderly and non-elderly in central urban area, Tianjin from 2006 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 46-54.
[8]	Yan Qinghu, Xue Feng, Yu Yong, Qin Yi, Yan Qingmei, Cui Jia. The value of ultrasound-guided microwave ablation in the treatment of localized tuberculous lesions [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 55-60.
[9]	Chen Jing, Qin Yali, Wang Mingdong, Yang Rubin, Wang Qian, Peng Yanqing, Qiu Jiyao, Zhang Xiao, Zhou Xinai. The value of QuantiFERON-TB Gold Plus in the clinical diagnosis of active pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 61-67.
[10]	Gu Jinhua, Zhang Panpan. Evaluation of the application value of three detection methods for Mycobacterium tuberculosis in a comprehensive hospital [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 68-72.
[11]	Yan Wenhua, Chen Wenjun. The value of digital health education in the preventive management of caregivers of patients with bacterial positive pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 73-78.
[12]	Liao Ying, Pang Yan, Zhao Jing, He Gaoqin, You Maolin, Wang Lei. Analysis on the reporting and case finding delay characteristics of pulmonary tuberculosis patients in Liangping District, Chongqing from 2018 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 8-13.
[13]	Zhang Ying, Guo Chunhui. Research progress in the treatment of tuberculous tracheobronchial stenosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 87-93.
[14]	Yang Shuqi, Li Feng. Advances in PD1/PD-L1 inhibitors in tuberculosis research [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 94-101.
[15]	Wei Xiaowen, Dong Ning, Shen Lei, Tao Yonghong, Wu Yuanhao, Zhang Lin. The lived experience and needs of parents caring for children with tuberculosis: a qualitative study [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 505-510.